In a nutshell This study investigated the effects of glucagon-like peptide 1 receptor agonists (GLP-1Ra) in patients with diabetes. They found that GLP-1Ra drugs improved cardiovascular (CV), kidney and mortality outcomes. Some background Type 2 diabetes (T2D) is caused by a reduced response to insulin. This is called insulin...
Read More
In a nutshell This study investigated the risk factors associated with diabetic retinopathy (DR). The authors concluded that factors such as age, total cholesterol, and the presence of other health complications could increase the risk of DR in patients with Type 2 diabetes (T2D). Some background T2D can lead to a number of other health...
Read More
In a nutshell This study assessed the effect of dulaglutide (Trulicity) on heart disease risk in patients with type 2 diabetes (T2D). The authors concluded that dulaglutide is an optimal treatment for patients with T2D at risk of heart disease. Some background While measures are put in place to protect heart health, diabetes increases the...
Read More
In a nutshell This study examined if dapagliflozin (Farxiga) and saxagliptin (Onglyza) improved symptoms of kidney disease in patients with type 2 diabetes and kidney disease. The authors concluded that dapagliflozin with or without saxagliptin reduced kidney disease symptoms and lowered blood glucose levels in these patients. Some background...
Read More
In a nutshell This study compared the safety and effectiveness of oral semaglutide with liraglutide administered via subcutaneous (under the skin) injection in patients with type 2 diabetes (T2D). The authors concluded that both treatments were similarly safe and effective in these patients. Some background Glucagon-like-peptide-1 (GLP1)...
Read MoreIn a nutshell This study evaluated the impact of long-term pioglitazone (Actos) treatment on outcomes for patients with type 2 diabetes (T2D) taking insulin. The authors concluded that this treatment lowered mortality risk for these patients. Some background As T2D progresses, more intensive treatment may be required. Typically, this means increasing...
Read MoreIn a nutshell This study examined whether diabetes is a risk factor for lower back pain (LBP). The authors concluded that male patients with diabetes may have a higher risk of developing LBP compared to female patients. Some background Patients with diabetes have a higher chance of developing chronic (long-term) health complications. ...
Read More
In a nutshell This study is investigating the safety and effectiveness of the EndoBarrier system for patients with poorly controlled type 2 diabetes (T2D) and obesity. The main outcome to be measured will be the change in blood glucose levels. This trial is recruiting in multiple locations across the United States. The details Bariatric surgery is the...
Read More
In a nutshell This study compared the effectiveness of adding sodium-glucose co-transporter (SGLT) inhibitors versus metformin (Glucophage) to insulin therapy for type 1 diabetes (T1D). This study concluded that SGLT inhibitors improved blood glucose control and weight loss better than metformin in these patients. Some background The goal of T1D...
Read More
In a nutshell This study evaluated the effects of alogliptin (Nesina) in elderly patients with type 2 diabetes (T2D). The authors concluded that alogliptin significantly lowered blood glucose levels for these patients, with minimal side effects. Some background As T2D progresses, more intense treatment may be required. Many patients with T2D...
Read More
In a nutshell This study compared two different diets to determine which improved symptoms of diabetes and overall health in patients with Type 2 diabetes (T2D). The authors concluded that the LCHP diet was better at reducing blood sugar levels, insulin levels, cholesterol, and fat levels compared to the CD diet. Some background One of the...
Read More
In a nutshell This study examined if long-term dulaglutide (Trulicity) treatment could reduce kidney disease symptoms in patients with Type 2 diabetes (T2D). The authors concluded that dulaglutide improved some symptoms of kidney disease over five years compared to placebo. Some background T2D often leads to long-term health...
Read More
